Market Overview

Bank of America Initiates Coverage on Jazz Pharmaceuticals Positive Outlook

Related JAZZ
Jazz Pharmaceuticals Up On Allergan, Inc. Rumor
Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs

In a report published Monday, Bank of America initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and $74 price objective.

Bank of America reported that, “We initiated coverage of Jazz with a Buy rating and $74 PO, which is based on a sum-of-the-parts DCF analysis and does not require multiple expansion. We like Jazz's focus on areas with strong growth potential and franchise durability, and we expect strong sales and EPS growth over the next several years driven by Xyrem and Erwinaze.”

Jazz Pharmaceuticals closed at $56.03 on Monday.

Latest Ratings for JAZZ

DateFirmActionFromTo
Aug 2014JP MorganInitiates Coverage onOverweight
Jul 2014Buckingham ResearchInitiates Coverage onBuy
Jul 2014SunTrust Robinson HumphreyInitiates Coverage onNeutral

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Analyst Ratings

 

Related Articles (JAZZ)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters